Literature DB >> 28412585

The promise of epigenetic therapy: reprogramming the cancer epigenome.

Andrew D Kelly1, Jean-Pierre J Issa2.   

Abstract

Epigenetics refers to heritable molecular determinants of phenotype independent of DNA sequence. Epigenetic features include DNA methylation, histone modifications, non-coding RNAs, and chromatin structure. The epigenetic status of cells plays a crucial role in determining their differentiation state and proper function within multicellular organisms. Disruption of these processes is now understood to be a major contributor to cancer development and progression, and recent efforts have attempted to pharmacologically reverse such altered epigenetics. In this mini-review we introduce the concept of epigenetic drivers of cancer and discuss how aberrant DNA methylation, histone modifications, and chromatin states are being targeted using drugs either in preclinical, or clinical development, and how they fit in the context of existing therapies.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28412585     DOI: 10.1016/j.gde.2017.03.015

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  63 in total

Review 1.  Polycomb repressive 2 complex-Molecular mechanisms of function.

Authors:  Valentina L Kouznetsova; Alex Tchekanov; Xiaoming Li; Xiaowen Yan; Igor F Tsigelny
Journal:  Protein Sci       Date:  2019-06-10       Impact factor: 6.725

2.  UBE3A Suppresses Overnutrition-Induced Expression of the Steatosis Target Genes of MLL4 by Degrading MLL4.

Authors:  Janghyun Kim; Bora Lee; Dae-Hwan Kim; Jae Gwang Yeon; Jeongkyung Lee; Younjung Park; Yuna Lee; Soo-Kyung Lee; Seunghee Lee; Jae W Lee
Journal:  Hepatology       Date:  2019-02-07       Impact factor: 17.425

3.  Epigenetic heterogeneity promotes acquired resistance to BET bromodomain inhibition in ovarian cancer.

Authors:  Yunheng Sun; Zhenfeng Zhang; Ke Zhang; Yuxia Liu; Peiye Shen; Meichun Cai; Chenqiang Jia; Wenjing Wang; Zhuowei Gu; Pengfei Ma; Huaiwu Lu; Lei Guan; Wen Di; Guanglei Zhuang; Xia Yin
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

4.  Chromatin Immunoprecipitation Followed by Next-Generation Sequencing (ChIP-Seq) Analysis in Ewing Sarcoma.

Authors:  Gwenneg Kerdivel; Valentina Boeva
Journal:  Methods Mol Biol       Date:  2021

Review 5.  Anticancer Effects of Nutraceuticals in the Mediterranean Diet: An Epigenetic Diet Model.

Authors:  Rosa Divella; Antonella Daniele; Eufemia Savino; Angelo Paradiso
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

Review 6.  X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis.

Authors:  Rossella Tricarico; Emmanuelle Nicolas; Michael J Hall; Erica A Golemis
Journal:  Clin Cancer Res       Date:  2020-07-30       Impact factor: 12.531

Review 7.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

8.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

9.  Epigenetic Alternations of MicroRNAs and DNA Methylation Contribute to Liver Metastasis of Colorectal Cancer.

Authors:  Jingwei Liu; Hao Li; Liping Sun; Shixuan Shen; Quan Zhou; Yuan Yuan; Chengzhong Xing
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

10.  DNA Mismatch Repair Deficiency Promotes Genomic Instability in a Subset of Papillary Thyroid Cancers.

Authors:  Mahsa Javid; Thanyawat Sasanakietkul; Norman G Nicolson; Courtney E Gibson; Glenda G Callender; Reju Korah; Tobias Carling
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.